CompletedNCT00374777
A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients
Medication studyAges 20–64JapanBipolarity
Understand this study
Who was this study for?
Listed age limits: 20 years to 64 years.
- Listed locations
- Chubu Region and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 450
- Sponsor
- Astellas Pharma Inc
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- From 20 Years to 64 Years
- Official registry ID
- NCT00374777
- Official title
Show the full official title
FK199B (Zolpidem MR Tablet) Phase III Clinical Study -A Double-Blind, Placebo- and Nitrazepam-Controlled, Group-Comparison Study in Patients With Insomnia Associated With Schizophrenia and Manic-Depressive Psychosis
Get this study by email
Recruitment & locations
CompletedChubu Region · Hokkaido Region · Kansai Region
3 more locations
- Kanto Region
- Kyushu Region
- Shikoku Region
Questions about this study
Who is behind this study?
The study sponsor is Astellas Pharma Inc, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including zolpidem MR, nitrazepam and placebo.
Who was this study for?
Listed age limits: 20 years to 64 years.
Want to explore more studies?
Explore studiesRelated studies
A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolarity type I- Long-term Extension Of Study SCA104779 (NCT00550407) -
A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression